First to the future of cardiac PET


CHICAGO, IL January 20, 2015 (PRNewswire) – Positron Corporation (OTCBB:POSC) is pleased to announce that the United States Patent and Trademark Office (USPTO) has awarded the Institute for Nuclear Research (INR) of the Russian Academy of Sciences a patent (U.S. No. 8,929,503) for the method for producing strontium-82 (Sr-82) - a precursor to rubidium-82 (Rb-82), the leading radiopharmaceutical used in Positron Emission Tomography (PET) myocardial perfusion imaging. It is the second patent for this technology in North America included in a license agreement between INR and Positron Corporation: INR has been awarded a Canadian patent (CA 2719347) for the same technology in July 2014. The rights to this patented technology have been granted by INR to Positron Corporation.  Although other licensees, from France and Russia, can sell Sr-82 produced with the patented technology, only Positron Corporation has the right to utilize the technology in North America.

The Sr-82 production technology was developed by Dr. Воris Zhuikov, Head of the Laboratory Radioisotope Complex and colleagues at INR.  The developed technology has significant environmental and economic benefits, as it simplifies the production process while markedly increasing the yield and quality of the Sr-82 product derived from rubidium metal.

This improved rubidium metal Sr-82 production process, currently practiced in Russia as well as by a French radioisotope production facility, will be applied to future rubidium metal target processing at Positron’s Texas facility.  The significant aspect of this technology is the potential realization of real-time, continuous Sr-82 production using a rubidium metal target loop on Positron’s proposed 70 MeV cyclotron.  

“Positron has been a strong advocate of the advancement, maturation, and implementation of this patented technology”, stated Jason Kitten, Executive Director of Radioisotopes for Positron Corporation. “We look forward to working with INR in building up the strontium-82 production infrastructure in the US and applying this proven radiostrontium production to our production capability. “

About Positron:

Positron Corporation is a nuclear medicine healthcare company that specializes in the business of cardiac PET imaging. Positron is vertically integrating critical segments of nuclear cardiology to provide an end-to-end solution for cardiac PET customers. The Company's products and services include positron emission tomography (PET) molecular imaging systems, clinical support, radioisotope processing and production services specifically for cardiac imaging. Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron’s unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. 

Forward Looking Statements: 

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.

For more information, contact:

Positron Corporation

Print this page